AGARWALEYE AGARWALEYE.NS · Stock Open AGARWALEYE in new tab
AGARWALEYE Analysis (AGARWALEYE.NS)
Is AGARWALEYE a good investment? AGARWALEYE (AGARWALEYE.NS) is currently trading at 500.15 INR. Market analysts have a consensus price target of 584.20 INR. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 109.31. This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule: AGARWALEYE is expected to release its next earnings report on Oct. 29, 2026. The market consensus estimate for Forward EPS is 8.40.
Investor FAQ
Does AGARWALEYE pay a dividend?
No, it does not currently pay a dividend.
What asset class is AGARWALEYE?
AGARWALEYE is classified as a Stock.
When is the next earnings date?
The next earnings date is projected to be Oct. 29, 2026. The company currently has a trailing EPS of 4.63.
Company Profile
Dr. Agarwal's Health Care Limited engages in running, owning, and managing eye care hospitals, opticals, pharmacies, etc. and related services in India and internationally. It offers femto cataracts, lenticular procedure, retinal surgeries, anterior segment reconstruction, and corneal transplants, as well as refractive and other surgeries. The company also develops, designs, manufactures, imports, and exports healthcare devices, which include ophthalmic diagnostic devices, such as auto perimeter, optical biometers, and ophthalmoscopes. In addition, the company offers consultations, diagnoses, and non-surgical treatments; and sells opticals, contact lenses and accessories, and eye care related pharmaceutical products. Dr. Agarwal's Health Care Limited was incorporated in 2010 and is based in Chennai, India.
Community Discussion